Kalinovich previously worked at Wabtec as a corporate vice president.
Azzur Group announced that James Kalinovich will be joining the company as chief financial officer. In the role, he will support the Azzur’s business units, including Azzur Cleanrooms on Demand, Azzur Labs, Azzur Consulting, and Azzur Training Center.
In a press release, Azzur Group’s CEO Michael Khavinson said, “We are pleased to welcome James to Azzur Group and look forward to his contributions as chief financial officer. I have complete confidence that the leadership and experience James brings to Azzur will continue to strengthen the company's foothold and prepare us for longstanding growth."
Prior to joining Azzur, Kalinovich worked as a corporate vice president and treasurer at Wabtec.
"I'm excited to join Azzur at such a pivotal time for the organization and build upon our attractive market position to instill long-term growth for the company," Kalinovich said in a press release. "I look forward to working alongside fellow leaders to continue to build on Azzur's strengths to increase returns while delivering unique value to our clients, communities, and employees."
(October 5, 2023); Azzur Group, LLC; Azzur Group Appoints James Kalinovich as Chief Financial Officer; https://www.prnewswire.com/news-releases/azzur-group-appoints-james-kalinovich-as-chief-financial-officer-301948894.html
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.